Publisher
Springer Science and Business Media LLC
Reference113 articles.
1. WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV [Internet]. WHO; 2020. http://www.who.int/hiv/pub/guidelines/ARV2018update/en/. Accessed 10 Feb 2020.
2. European AIDS Clinical Society. Initial Regimens: ART-naïve Adult [Internet]. EACS Guidel; 2020. https://eacs.sanfordguide.com/art/initial-regimens-arv-naive-adults. Accessed 17 Nov 2020.
3. Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18:357.
4. Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS Lond Engl. 2017;31:2503–14.
5. Swindells S, Andrade-Villanueva J-F, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112–23.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献